Drug Profile
BV 5200
Alternative Names: Cardiclear; HYAL BV5200Latest Information Update: 19 Dec 2006
Price :
$50
*
At a glance
- Originator SkyePharma Inc
- Class Anti-ischaemics
- Mechanism of Action CD44 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Coronary artery restenosis
Most Recent Events
- 17 Dec 1998 Suspended-II for Coronary artery restenosis in Canada (IV)
- 29 May 1995 Phase-I clinical trials for Coronary artery restenosis in Canada (IV)
- 29 May 1995 Preclinical development for Coronary artery restenosis in United Kingdom (IV)